mRNA Vaccine Cuts COVID-Related Guillain-Barré Risk
COVID-19 increases the risk for Guillain-Barré syndrome sixfold, while getting the Pfizer mRNA vaccine lowers risk.
Stay updated with breaking news from Anat Arbel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
COVID-19 increases the risk for Guillain-Barré syndrome sixfold, while getting the Pfizer mRNA vaccine lowers risk.
Odds ratio of 6.30 for Guillain-Barré syndrome association with SARS-CoV-2 infection and 0.41 for COVID-19 vaccine administration.
New research from medical institutes in Israel has found that individuals who have been infected with Covid-19 are at an increased risk of developing Guillain-Barre syndrome in the six weeks following the infection.
COVID infection can raise the risk of a rare immune system attack on the body's nerves -- but vaccination might protect against it, a large new study suggests.
Washington, Oct 18 (Prensa Latina) A new study from Israel ties Covid-19 infection to an increased risk of a diagnosis of Guillain-Barre syndrome (GBS) within 6 weeks, while mRNA vaccination was linked to a decreased risk of the rare but serious autoimmune disease.